PMID- 6225247
OWN - NLM
STAT- MEDLINE
DCOM- 19831008
LR  - 20190819
IS  - 0042-9007 (Print)
IS  - 0042-9007 (Linking)
VI  - 45
IP  - 2
DP  - 1983
TI  - S-sulfonation: a reversible chemical modification of human immunoglobulins 
      permitting intravenous application. II. Effect on Fc-mediated effector functions.
PG  - 155-65
AB  - The generation and release of mediators of inflammation and anaphylaxis via 
      activation of complement or of Fc receptor-bearing cells is held responsible for 
      adverse reactions observed upon intravenous administration of standard 
      immunoglobulins. They are caused by immunoglobulin G (IgG) effector functions 
      predominantly located in the Fc region of the molecule and 'activated' by 
      aggregate formation. Their functional activity depends on the correct 
      conformation of the C gamma 2 domains of Fc and are therefore impaired or even 
      abrogated by S-sulfonation of the hinge disulfide bonds, as demonstrated in this 
      communication: S-sulfonated IgG (S-IgG) has no anticomplementary activity and 
      does not interact with Fc-receptors anymore. After antigen binding, i.e. immune 
      complex (IC) formation, sulfonated IgG is about half as potent as standard IgG in 
      complement activation or phagocyte stimulation (human monocytes and 
      granulocytes). The two activities synergize, however, so that in the presence of 
      complement S-IgG IC are as effective phagocyte activators as standard IC. 
      Moreover, S-sulfonation being the only chemical modification of immunoglobulins 
      that is reversible, it can be demonstrated that all IgG effector functions 
      important for antigen removal are regained by reconstitution of the disulfide 
      bonds.
FAU - Hofstaetter, T
AU  - Hofstaetter T
FAU - Gronski, P
AU  - Gronski P
FAU - Kanzy, E J
AU  - Kanzy EJ
FAU - Schorlemmer, H U
AU  - Schorlemmer HU
FAU - Seiler, F R
AU  - Seiler FR
LA  - eng
PT  - Journal Article
PL  - England
TA  - Vox Sang
JT  - Vox sanguinis
JID - 0413606
RN  - 0 (Antigen-Antibody Complex)
RN  - 0 (Complement Inactivator Proteins)
RN  - 0 (IgG, sulfonated)
RN  - 0 (Immunoglobulin G)
RN  - 0 (Receptors, Fc)
RN  - 0 (Receptors, IgG)
RN  - 0 (Staphylococcal Protein A)
RN  - 298-83-9 (Nitroblue Tetrazolium)
SB  - IM
MH  - Antigen-Antibody Complex/metabolism
MH  - Binding, Competitive
MH  - Blood Bactericidal Activity
MH  - Complement Inactivator Proteins/physiology
MH  - Humans
MH  - Immunoglobulin G/administration & dosage/*physiology
MH  - Luminescent Measurements
MH  - Lysosomes/enzymology
MH  - Nitroblue Tetrazolium
MH  - Phagocytes/metabolism
MH  - Phagocytosis
MH  - Pinocytosis
MH  - Receptors, Fc/*metabolism
MH  - Receptors, IgG
MH  - Rosette Formation
MH  - Staphylococcal Protein A/metabolism
EDAT- 1983/01/01 00:00
MHDA- 1983/01/01 00:01
CRDT- 1983/01/01 00:00
PHST- 1983/01/01 00:00 [pubmed]
PHST- 1983/01/01 00:01 [medline]
PHST- 1983/01/01 00:00 [entrez]
AID - 10.1111/j.1423-0410.1983.tb01900.x [doi]
PST - ppublish
SO  - Vox Sang. 1983;45(2):155-65. doi: 10.1111/j.1423-0410.1983.tb01900.x.